Safety, Tolerability and Efficacy of SPD503 in Treating ADHD in Children Aged 6-17

Summary

The purpose of this study is to determine the effects of SPD503 compared to placebo on tasks of sustained attention in children and adolescents aged 6-17 diagnosed with ADHD.

Timeline

Start

2005-05-12

Primary completion

2005-10-05

Completion

2005-10-05

Publications

• Results Kollins SH, Lopez FA, Vince BD, Turnbow JM, Farrand K, Lyne A, Wigal SB, Roth T. Psychomotor functioning and alertness with guanfacine extended release in subjects with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2011 Apr;21(2):111-20. doi: 10.1089/cap.2010.0064. Epub 2011 Apr 10.

Drugs

Indications